Seagen Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT00529503
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of California at Los Angeles, Los Angeles, California, United States
πΊπΈStanford University Medical Center, Stanford, California, United States
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT00528333
- Locations
- πΊπΈ
Southern Cancer Center, Mobile, Alabama, United States
πΊπΈTower Cancer Research Foundation, Beverly Hills, California, United States
πΊπΈGlendale Memorial Hospital, Glendale, California, United States
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00525447
- Locations
- πΊπΈ
Rocky Mountain Cancer Center, Denver, Colorado, United States
πΊπΈH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00502112
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈRocky Mountain Cancer Center, Denver, Colorado, United States
πΊπΈGeorgetown University, Washington, District of Columbia, United States
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00435916
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈMayo Clinic-Arizona, Scottsdale, Arizona, United States
πΊπΈUniversity of California Los Angeles, Los Angeles, California, United States
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
- Conditions
- Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00430846
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈWashington University, St. Louis, Missouri, United States
πΊπΈWeill Cornell Medical College, New York, New York, United States
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaMyeloproliferative DisordersMyelodysplastic SyndromeChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT00283114
- Locations
- πΊπΈ
Rocky Mountain Cancer Center, Denver, Colorado, United States
πΊπΈCancer Care Specialists of Central Illinois, Decatur, Illinois, United States
πΊπΈIndiana Oncology-Hematology Consultants, Indianapolis, Indiana, United States
A Safety Study in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Leukemia, Lymphocytic, Chronic
- Interventions
- Drug: SGN-40 (anti-huCD40 mAb)
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00283101
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
πΊπΈWeill Medical College/Cornell University, New York, New York, United States
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Drug: SGN-40 (anti-huCD40 mAb)
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00103779
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University, Stanford, California, United States
πΊπΈUniversity of Miami, Miami, Florida, United States
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
- Conditions
- Large Cell Lymphoma
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00099255
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of California at Los Angeles, Los Angeles, California, United States
πΊπΈStanford University, Stanford, California, United States